Synthesis and Evaluation of Phorboid 20-Homovanillates: Discovery of a Class of Ligands Binding to the Vanilloid (Capsaicin) Receptor with Different Degrees of Cooperativity
Abstract:
A number of phorboid 20-homovanillates were prepared by condensation of phorbol 12,13-diesters and 12-dehydrophorbol 13-esters with Mem-homovanillic acid followed by removal of the protecting group with SnCl4 in THF. These compounds were evaluated for their ability to inhibit [3H]resiniferatoxin (RTX) binding to rat spinal cord membranes. Compounds bearing a lipophilic ester group on ring C were considerably active, but a surprising tolerance of the vanilloid receptor toward the location and the orientation of this ester group was disclosed. Unexpectedly, these ligands could also diminish, to a variable degree, the positive cooperativity which characterizes RTX binding to the vanilloid receptor. Phorbol 12-phenylacetate 13-acetate 20-homovanillate (PPAHV, 6a), a compound which abolished binding cooperativity, was further tested in a variety of in vivo assays used to characterize vanilloid-like activity. PPAHV showed only a marginal pungency and failed to induce a measurable hypothermia response at doses (up to 200 mg/kg) at which it effectively desensitized against neurogenic inflammation. These data suggest that the peculiar binding behavior of these ligands might be associated with a distinct spectrum of biological activity.
Capsaicin (CPS, 1), the pungent principle of
hot
pepper, excites and then desensitizes a subset of primary sensory neurons involved in nociception, neurogenic inflammation, thermoregulation, and a variety of
local regulatory functions.1,2
RTX is structurally related to phorbol esters, but it neither acts as a tumor-promoter17 nor binds to the PKC isoforms targeted by phorbol esters.15 Though structurally and biogenetically unrelated in their carbon skeleton, RTX and CPS share a vanillyl (4-hydroxy-3-methoxybenzyl) moiety which is essential for their biological activity; thus the common membrane recognition site for these compounds was named the 'vanilloid' receptor.18 Specific binding of [3H]RTX provided the first direct proof for the existence of this receptor19 and was then used to visualize CPS-sensitive neurons by an autoradiographic approach and to explore their pharmacology.20
As a general rule, vanilloid receptors bind CPS and
RTX in a positive cooperative fashion.21 The
biological
role for this binding behavior is unknown, but it might
well serve to amplify the effects of endogenous
ligand(s) produced in critically low concentrations.22
Positive
binding cooperativity thus points to the existence of
endogenous vanilloids. Although RTX mimics CPS
qualitatively, it shows striking differences in potency
relative to CPS, ranging from several thousandfold
higher potency to equipotency depending on the biological end points examined.15,18 Moreover, RTX also
has
unique actions, which might contribute to its broad
therapeutic range. For example, unlike capsaicin, RTX
is able to desensitize certain end points (e.g., pulmonary
J1 receptors) without any apparent prior
excitation.15,18
As yet, it is unclear to what extent these
differences
between RTX and CPS actions reflect receptor heterogeneity, but the observation that vanilloids show different structure-activity relations for receptor binding
and stimulation of calcium uptake, respectively, suggests the existence of distinct receptor
subclasses.23,24
Capsaicinoids are relatively simple from the structural point of view, and their structure-activity relationships have been explored in depth.7-13 By contrast, limited information exists on the RTX pharmacophore.15,23-25 The homovanillyl residue at C-20 and the lipophilic orthoester group on ring C are both necessary for the activity,15 but the key elements of the terpenoid core are still ill defined, since RTX is not commercially available in synthetically useful amounts and is of difficult and limited accessibility from natural sources.
The therapeutical potential of RTX26 has
stimulated
synthetic activity aimed at the total synthesis of the
biologically active portion of the molecule and eventually
of RTX itself.27 In the context of a more modest
but
potentially rewarding project, we have investigated the
possibility to obtain vanilloids structurally related to
RTX using phorbol as starting material. This compound
is related to the terpenoid core of RTX (resiniferonol),
and the acylation of certain phorbol-related diterpenoids
[12-deoxyphorbol 13-phenylacetate, 20-deoxy-20-aminophorbol 12,13-bis(benzoate)] with homovanillic
acid
has already yielded vanilloids with unique
activity.25,28
However, the possibility of using phorbol itself for
the
synthesis of vanilloids has so far been largely unaddressed, despite its availability from a commercial
source (croton oil)29 and the fact that its chemistry
has
been extensively investigated,29 affording a large
pool
of related substrates (phorbobutanone, crotophorbolone,
4-phorbol, neophorbol, phorboisobutanone)29 to test
the
topology of the vanilloid binding site.
In spite of these potential advantages, the development of phorbol-based ligands has so far been hampered by the lack of an efficient synthetic method for the preparation of 20-homovanillyl esters of these functionalized tiglianes.30 We report here an efficient protocol to solve this problem and the biological evaluation of a series of phorbol 20-homovanillates prepared in this way.
Using known phorbol chemistry,29 the 12-acyl 13-acetyl diesters 5a-f were prepared from phorbol 13-acetate 20-trityl ether (4a) (Scheme 1).31 To investigate the introduction of the homovanillyl group, the primary allylic alcohol at C-20 was esterified with a series of protected [acetyl (Ac), triethylsilyl (Tes), methoxymethyl (Mom), (methoxyethoxy)methyl (Mem)] homovanillic (HMV) acids, and the deprotection was tested under standard conditions (pyrrolidine-water or NaHCO3 for the acetyl group,27 fluorides for the Tes group, H+ or Lewis acids (ZnBr2, MgBr2) for the Mom, Mem, and Tes groups). Mixtures of products were obtained, resulting from competitive hydrolysis of the 12- and 13-esters, loss of the homovanillyl moiety, and/or degradation of the acid- and base-sensitive terpenoid core. After considerable experimentation, we eventually found that the Mem group could be removed in high yield with SnCl4 in THF. In these conditions, the Mom group could not be cleaved so effectively, presumably because of poorer chelation. SnCl4 is insoluble in THF, but, as the reaction proceeded, a homogeneous solution was obtained. The slow delivery of the oxyphilic species is important, since in CH2Cl2 the yield was lower and byproducts were observed. This protocol to introduce the homovanillyl moiety (esterification with Mem-HMV acid and deprotection with SnCl4 in THF) was used throughout.
![]() | Scheme 1 a |
Attempts to prepare analogues of the type 7, with a reverse location of the 12,13-diester groups, failed, since acyl rearrangement took place in the acetylation of 13-acylphorbol 20-trityl ethers. Thus, treatment of 13-(phenylacetyl)phorbol 20-trityl ether (4b) with acetic acid-DCC gave phorbol 12-phenylacetate 13-acetate 20-trityl ether (8a) as the major reaction product, along with the 12-monoester 8b (Scheme 2). 8a was also the major reaction product when the acetylation was carried out with Ac2O-pyridine or acetyl choride-triethylamine. The location of the ester group of 8a was verified by NOESY spectroscopy and further confirmed by inspection of the long-range (HMBC) spectrum of the homovanillate 6a obtained from this compound.
![]() | Scheme 2 a |
The 12,13-bis(phenylacetate) 20-homovanillate
10
was prepared from the corresponding 20-trityl ether
(Scheme 3). The 12-dehydrophorbol
homovanillates
12a,b were prepared from the corresponding
13-esters
by oxidation (PCC) and homovanyllation in the usual
way (Scheme 4), and
the 3-alcohol 13 was prepared
from the borohydride reduction of the enone 6a
under
Luche conditions.32 The acetate 14 was
prepared by
esterification of 5a with acetylhomovanillic
acid.33
![]() |
![]() | Scheme 3 a |
![]() | Scheme 4 a |
From the radioligand binding experiments listed in
Table 1, it is evident that, with the exception
of 6f, 12a,
and 13, all the ligands synthesized are more potent
than
capsaicin to compete for specific [3H]RTX binding
sites
in rat spinal cord membranes, although none of them
approached the very high affinity (20 pM) of RTX.
Parameters of RTX binding to rat spinal cord membranes were analyzed in the presence of increasing
concentrations (6-400 pM) of [3H]RTX and the
concentration of phorboid 20-homovanillates which inhibited
RTX binding by 50% in the competition experiments.
It turned out that those ligands which competed for
RTX
binding sites also reduced the positive cooperativity
characteristic of RTX binding to rat spinal cord membranes (Table 1, Figure 1). There appears to
be little
or no correlation between binding affinities and apparent Hill coefficients. The maximal density of binding
sites (Bmax values) was, however, not affected.
6a also
inhibited RTX binding to rat urinary bladder (Ki
= 2.0
M) membranes (a single experiment, not shown).
6a
and RTX showed the same rank order of affinity using
rat, porcine, and human spinal cord preparations (rat
> pig > human). Inhibitory constants (Ki)
for RTX were
54 ± 6 pM in rat, 120 ± 15 pM in pig, and 450 ± 52
pM
in human spinal cord, respectively (mean ± SEM, three
determinations). 6a inhibited
[3H]RTX binding to rat,
pig, and human spinal cord membranes with Ki
values
of 0.6 ± 0.3, 2.1 ± 0.4, and 6.4 ± 1.2
M,
respectively
(mean ± SEM, three measurements). As 6a is
a
vanilloid receptor agonist in in vitro calcium
influx
experiments,34 this ligand was further characterized
in
a variety of in vivo assays used to measure
vanilloid-like activity. 6a was approximately 100-fold less
potent
than capsaicin to provoke eye-wiping movements when
instilled into the eye of rats (Figure
2). At doses up to
10 mg/ear, 6a failed to induce an erythema
response
(not shown). When given sc, 6a, up to 200 mg/kg,
did
not cause any measurable hypothermia response (30
min, 1 h, 2 h postinjection) (Figure 3A),
although at the
examined doses it desensitized against RTX-induced ear
edema formation (with an estimated ED50 of 10
mg/kg,
determined 24 h after the administration of 6a)
and
depleted vanilloid receptors from the spinal cord (Figure
3B). The subcellular mechanism(s) underlying in
vivo
vanilloid receptor loss following systemic vanilloid
treatment is(are) essentially unknown, but this
receptor
loss is entirely due to a reduction of
Bmax.35 In
parallel
experiments, both RTX (with an ED50 of 3
g/kg)
and
capsaicin (with an ED50 of 3 mg/kg) induced a
maximal
(approximately 4
C) drop in rectal temperature when
measured 1 h after treatment (Figure 3A).
Phorbol 12-phenylacetate 13-acetate 20-homovanillate (PPAHV, 6a) inhibited specific binding of
[3H]RTX
to vanilloid receptors in rat spinal cord membranes with
an affinity (Ki = 0.6 M) higher than that
of capsaicin
(Ki = 2.0
M) but lower than that of RTX
(Ki = 20 pM)
(Table 1). Replacement of the phenylacetyl moiety
with
related acids containing a lipophilic aromatic group
[benzoic (6b), p-azidophenylacetic
(6c), p-azidobenzoic
(6d)] led to a modest increase of the affinity, as
did
replacement with a cyclohexylacetyl group (6e),
whereas
a cyclohexanecarboxylate group decreased the activity
(6f). None of these compounds approached the
affinity
of RTX, but their activity is surprising, since all diterpenoid ligands of the vanilloid receptors reported to date
have a lipophilic ester group on the opposite (
) face
of
ring C.15,23-25,28
Comparison of the 12-phenylacetyl 13-acetyl derivative 6a and the 12,13-bis(phenylacetyl) derivative 10 showed that the presence of lipophilic ester groups on both faces of ring C increases the affinity. However, comparison of 6a-f with compounds having an inverted location of the ester groups in the northern hemisphere (that is, 12-acetyl 13-acyl phorbol esters like 7) could not be done, since acyl rearrangement took place in the acetylation of the 13-acyl derivatives, affording 12-acyl 13-acetyl esters as the major reaction products (Scheme 2).36
The importance of a lipophilic ester group on ring C
is highlighted by comparison of the activity of the 12-dehydrophorbol ligands 12a,b. Indeed, only the
13-phenylacetate 12b was active, whereas the
13-acetate
12a was devoided of activity. Reduction of the
carbonyl
group of 6a gave the 3-alcohol 13 and caused
a
dramatic loss of activity. This finding epitomizes
the
strict structural requirements necessary for vanilloid
activity and suggests that the C-3 carbonyl is involved
in receptor binding.
We have recently reported that 6a can abolish positive cooperativity of binding by the vanilloid receptor.34 As predicted by the modified Hill equation for positive binding cooperativity, an initial enhancement by nonradioactive RTX of specific [3H]RTX binding was seen at low fractional receptor occupancies, preceding inhibition.34 In parallel experiments, 6a failed to enhance specific RTX binding,34 in accordance with a noncooperative binding mechanism. Table 1 shows that this behavior is not unique of 6a. Indeed, those phorboid 20-homovanillates which competed for specific RTX binding sites also reduced positive cooperativity of binding, suggesting that this binding behavior is a ligand-induced feature rather than an inherent property of vanilloid receptors. The molecular mechanism(s) responsible for positive cooperative binding is(are) essentially unknown. It is, however, generally accepted that positive cooperativity represents a self-regulatory process in which the binding of a ligand molecule to a member of a receptor oligomer increases the affinity of the other members of the same receptor oligomer for additional molecules. Inasmuch, positive binding cooperativity reflects conformational changes in the receptor protein. Our present finding that phorboid 20-homovanillates bind to vanilloid receptors with dissimilar Hill coefficients is consistent with the view that different ligand-receptor complexes may have different molecular conformations,37 resulting in different degrees of binding cooperativity.
The synthesis of the phorboid homovanillate ligands reported in Table 1 is straightforward and could be scaled to gram amounts (see the Experimental Section). We have thus been able to test 6a in a variety of in vivo assays used to characterize vanilloid-like activity. 6a showed only a marginal pungency (Figure 2) and failed to induce an ear erythema response. Furthermore, no hypothermic response (Figure 3A) could be observed in the rat at doses at which 6a could effectively desensitize against neurogenic inflammation and deplete vanilloid receptor in the spinal cord (Figure 3B). The marginal activity of topical 6a to induce acute ocular pain (as quantified by counting protective eye wipings) might simply be a pharmacokinetical artifact. For example, tinyatoxin, an RTX analogue lacking the methoxyl on the 20-ester group, is likewise inactive in the eye-wiping assay, although it is only 5-10-fold less potent than RTX to induce other biological responses, including hypothermia.15,18 However, the failure of systematically administered 6a to reduce body temperature more likely reflects receptor heterogeneity. 12-Deoxyphorbol 13-phenylacetate 20-homovanillate is also a very weak inducer of the hypothermia response,28 suggesting that the vanilloid receptor mediating this response is particularly sensitive to changes in the diterpene moiety. This finding might be of great practical importance for drug development, since hypothermia is a clearly undesirable side effect of vanilloid treatment. The relationship between the peculiar spectrum of biological activity of 6a and its noncooperative binding to vanilloid receptor remains to be established. A comparison of the biological activity of phorboid 20-homovanillates with different degrees of binding cooperativity is expected to reveal the biological relevance of this binding behavior.
Alkylation or acylation of the phenolic hydroxyl
reduces or completely removes the activity of capsaicinoids.11 Interestingly, phorboid ligands seem to
tolerate
better these chemical modifications. For example,
acetyl RTX is comparable in potency to RTX in the
mouse erythema assay,38 whereas the
homoveratryl
analogue of RTX binds to rat spinal chord membranes
with only 8-fold less affinity than does RTX.39
In
keeping with this, acetylation of the phenolic hydroxyl
of 6a resulted in a minimal drop in activity (14,
Table
1). Removal of the homovanillyl moiety caused instead
a complete loss of activity (Ki > 200 M for
5a).
The extraordinary potency of RTX is presumably the
result of an ideal alignment between the terpenoid core,
the lipophilic orthoester group on the -face of ring C,
and the C-20 homovanillate. The activity of the homovanillates 6a-f, which lack a lipophilic residue on
the
-face of ring C, and 10 and 12b, where the
9,13,14-o-phenylacetate is replaced by a 13-phenylacetate, points
to the possibility of alternative alignments. These,
although less efficient in terms of affinity, might be
useful to dissect receptor subclasses, ultimatively leading to more selective and therapeutically useful second-generation vanilloids.
WARNING: 12,13-Diesters of phorbol are powerful tumor promoters and irritants.29 Great care should thus be taken in the manipulation of 5a-f and related compounds with a free 20-hydroxyl, and all diterpene intermediates and final products should be treated as potentially dangerous compounds.
General Methods. Anhydrous conditions were
achieved
(when indicated) by flame-drying flasks and equipment.
Reactions were monitored by TLC on Merck 60 F254 (0.25 mm)
plates, which were visualized with 5%
H2SO4 in EtOH and
heating. Merck silica gel (70-230 mesh) was used for
open-column chromatography. A Waters microporasil column
(0.8
× 30 cm) was used for HPLC, with detection by a Waters
differential refractometer 340. Isocratic solvent systems
of
composition stated in the text were used to assess the
purity
of the compounds. Melting points were obtained on a
Büchi
SMP-20 apparatus and are uncorrected. 1H-NMR (300
MHz)
and 13C-NMR (75 MHz) spectra were recorded on a
Bruker
AC-300 spectrometer at 25 C. The spectra were fully
assigned
using two-dimensional techniques [2J and
3J (HMBC)
1H-13C
correlations].
Materials. [3H]RTX (37 Ci/mmol) was synthesized by the Chemical Synthesis and Analysis Laboratory, NCI-FCRDC, Frederick, MD, and kindly donated by Dr. P. Blumberg (NCI, Bethesda, MD). Homovanillonitrile for the synthesis of Mem-homovanillic acid (Mem-HMVA) was purchased by Aldrich, and croton oil for the isolation of phorbol29 was from Calbiochem-Novabiochem AG. Commercially available reagents and solvents were used without further purification. CH2Cl2 was dried by distillation from CaH2 and THF by distillation from sodium benzophenone.
3-Methoxy-4-[(2-methoxyethoxy)methoxy]phenylacetic Acid (Mem-homovanillic acid). To a solution of
homovanillonitrile (4.0 g, 24.5 mmol) in dry
CH2Cl2 (15 mL) were
added N-ethyldiisopropylamine (13.97 mL, 10.3 g, 81.2
mmol,
3.3 equiv) and Mem-chloride (9.28 mL, 13.2 g, 81.2 mmol,
3.3
equiv). The reaction mixture was stirred at room
temperature
for 48 h and then diluted with CH2Cl2 (ca.
40 mL), washed
with dilute HCl (2 × 15 mL), saturated NaHCO3 (2 × 15
mL),
and brine, and dried (Na2SO4).
Removal of the solvent left an
oil, which was dissolved in 10 mL of EtOH; 15 mL of 6.6 N
KOH was then added, and the solution was refluxed for 12 h
under a nitrogen atmosphere. After cooling and dilution
with
water (ca. 50 mL), the solution was extracted wtih EtOAc
(2
× 15 mL). The pH of the aqueous phase was adjusted to
3.0-3.5 with concentrated HCl, and the suspension was extracted
with EtOAc (4 × 20 mL). The organic phase was washed
with
brine, dried (Na2SO4), and evaporated.
The residue was
crystallized from ether to give 4.08 g (62%) of a pale
yellow
powder: mp 59 C; IR (KBr) 3400-2800 (br), 1701, 1514,
1261,
1217, 1101, 1001 cm-1; MS (EI) m/e
270 (M+) (20), 149 (70),
89 (100), 59 (90), 43 (35); 1H NMR (300 MHz,
CDCl3)
10.80
(br s, 1H), 7.15 (br d, J = 7.8 Hz, 1H), 6.82 (br s, 1H),
6.80 (br
d, J = 7.8 Hz, 1H), 5.30 (s, 2H), 3.86 (s, 2H), 3.85 (m,
3H),
3.59 (s, 2H), 3.57 (m, 2H), 3.38 (s, 3H). Anal.
(C13H18O6) C,
H.
General Procedure for the Synthesis of Phorboid 20-Homovanillates from Phorboid 20-Trityl Ethers: Synthesis of Phorbol 12-Phenylacetate 13-Acetate 20-Homovanillate (PPAHV, 6a). (a) To a solution of phorbol
13-acetate 20-trityl ether (4a)30 (4.93 g, 7.6 mmol)
in dry CH2Cl2
(110 mL) were added dicyclohexylcarbodimide (DCC; 4.70 g,
22.8 mmol, 3 equiv), phenylacetic acid (3.1 g, 22.8 mmol,
3
equiv), and 4-(dimethylamino)pyridine (DMAP; 50 mg).
After
stirring for 90 min at room temperature, the reaction
mixture
was diluted with ether (ca. 100 mL) and filtered to remove
the precipitate of dicyclohexylurea (DCU). The filtrate
was
washed with brine (2 × 30 mL), dried
(Na2SO4), and evaporated. The residue, still containing DCU, was dissolved in
0.01
N methanolic HClO4 (200 mL). After stirring at room
temperature for 50 min, the solution was diluted with water
(ca.
400 mL), neutralized with solid NaOAc, and extracted with
petroleum ether and then CHCl3. The chloroform phase
was
washed with brine, dried (Na2SO4), and
evaporated to give 4.6
g of a solid residue. Part of this (460 mg) was purified
by
column chromatography (7 g of silica gel,
hexane-EtOAc, 3:7,
as eluant) to give 290 mg (73% from 4a) of 5a as
a white
powder: mp 104 C; IR (KBr) 3300, 1730, 1460, 1320,
1240,
980 cm-1; MS (CI, isobutane) m/e
525 (M+ + H) (100); 1H NMR
(300 MHz, CDCl3)
7.56 (br s, H-1), 7.29 (m,
PhCH2CO), 5.64
(d, J = 5.4 Hz, H-7), 5.53 (br s, OH), 5.40 (d,
J = 10.5 Hz,
H-12), 4.02 (d, J = 13.3 Hz, H-20a), 3.96 (d, J
= 13.3 Hz,
H-20b), 3.66 (d, J = 14.7 Hz,
PhCH2CO), 3.62 (d, J = 14.7
Hz,
PhCH2CO), 3.20 (br s, H-8, H-10), 2.55 (br d,
J = 19.5 Hz,
H-5a), 2.46 (br d, J = 19.5 Hz, H-5b), 2.07 (s, Ac), 1.76
(d, J =
1.6 Hz, H-19), 1.08 (s, H-16), 1.01 (s, H-17), 0.84 (d, J
= 6.4
Hz, H-18).
To avoid unnecessary manipulation of dangerous products,29 the crude diesters were directly used for the esterification with Mem-homovanillic acid. When the procedure was tested on both purified and crude diesters (compounds 5a,b), no detrimental decrease of the yield was observed.
(b) To a solution of crude phorbol 13-acetate
12-phenylacetate (5a) [2.70 g, corresponding to 1.70 g (3.24 mmol)
of
pure diester on the basis of the extrapolated yield] in 70
mL
of dry CH2Cl2 were added Mem-homovanillic
acid (1.74 g, 6.48
mmol, 2 equiv), DCC (1.33 g, 6.48 mmol, 2 equiv), and DMAP
(50 mg). After stirring for 1 h at room temperature,
the
solution was diluted with ether (70 mL) and filtered.
The
filtrate was washed with brine, dried
(Na2SO4), and evaporated. The residue was purified by column
chromatography
(50 g of silica gel, hexane-EtOAc, 3:7, as eluant) to give
2.360
g (94%) of the 20-Mem-homovanillate as a white powder:
mp
85 C; IR (KBr) 3400, 1740, 1380, 1320, 1220, 1130, 990
cm-1;
MS (CI, isobutane) m/e 777 (M+ +
H) (100); 1H NMR (300 MHz,
CDCl3)
7.55 (s, H-1), 7.29 (m,
PhCH2CO), 7.11 (br d, J =
8.1
Hz, 6-HMV), 6.80 (br s, 2-HMV), 6.75 (d, J = 8.1 Hz,
5-HMV),
5.63 (br s, H-7), 5.48 (br s, OH), 5.39 (d, J = 10.4 Hz,
H-12),
5.28 (s, 2H, Mem), 4.49 (d, J = 12.4 Hz, H-20a), 4.46 (d,
J =
12.4 Hz, H-20b), 3.85 (s, HMV-OMe), 3.84 (m, 2H, Mem),
3.69
(d, J = 14.7 Hz, PhCH2CO), 3.65 (d,
J = 14.7 Hz, PhCH2CO),
3.55 (m, 2H, Mem), 3.55 (br s, HMV-CH2), 3.36 (s,
Mem-OMe),
3.16 (br s, H-8, H-10), 2.40 (d, J = 19.0 Hz, H-5a), 2.36
(d, J
= 19.0 Hz, H-5b), 2.09 (m, H-11), 2.07 (s, Ac), 1.76 (br s,
H-19),
1.07 (s, H-16), 0.99 (s, H-17), 0.96 (d, J = 5.4 Hz,
H-14), 0.83
(d, J = 6.4 Hz, H-18).
(c) To a solution of the Mem-homovanillate (1.33 g,
1.71
mmol) in dry THF (100 mL) was added SnCl4 (1.00 mL,
2.23
g, 8.6 mmol, 5 equiv) dropwise. During the addition, a
white
precipitate was formed, which then dissolved as the
reaction
proceeded. After stirring for 90 min under a nitrogen
atmosphere, the reaction mixture was worked up by the addition
of saturated NaHCO3 (ca. 25 mL) and extracted with
EtOAc
(2 × 50 mL). After washing with brine, drying
(Na2SO4), and
evaporation, the residue was purified by column chromatography (25 g of silica gel, hexane-EtOAc, 7:3, as eluant) to
give
1.57 g (76%) of 6a as a white powder: mp 75 C; IR
(KBr)
3420, 1740, 1390, 1275, 1150, 1040, 990 cm-1; MS
(CI,
isobutane) m/e 689 (M+ + H)
(100); 1H NMR (300 MHz, CDCl3)
7.53 (s, H-1), 7.27 (m, PhCH2CO), 6.79
(br d, J = 8.0 Hz,
6-HMV), 6.77 (br s, 2-HMV), 6.72 (br d, J = 8.0 Hz,
5-HMV),
5.57 (br s, OH), 5.53 (br s, H-7), 5.43 (br s, OH), 5.38 (d,
J =
10.6 Hz, H-12), 4.51 (br d, J = 12.8 Hz, H-20a), 4.42 (br
d, J
= 12.8 Hz, H-20b), 3.87 (OMe), 3.64 (d, J = 14.7
Hz,
PhCH2CO), 3.62 (d, J = 14.7 Hz,
PhCH2CO), 3.50 (br s, HMV-CH2), 3.12 (br s, H-8, H-10), 2.41 (br d,
J = 19.1 Hz, H-5a),
2.27 (br d, J = 19.1 Hz, H-5b), 2.07 (s, Ac), 2.07 (m,
H-11),
1.76 (br s, H-19), 1.05 (s, H-16), 0.99 (s, H-17), 0.88 (d,
J = 5.1
Hz, H-14), 0.81 (d, J = 6.2 Hz, H-18); 13C NMR
(75 MHz,
CDCl3)
160.5 (d, C-1), 135.3 (s, C-2), 208.1 (s, C-3),
73.5 (s,
C-4), 38.7 (t, C-5), 132.7 (s, C-6), 131.9 (d, C-7), 39.2 (d,
C-8),
78.0 (s, C-9), 56.1 (d, C-10), 42.8 (d, C-11), 77.4 (d, C-12),
65.4
(d, C-13), 36.0 (d, C-14), 25.8 (s, C-15), 23.5 (q, C-16), 16.3
(q,
C-17), 14.2 (q, C-18), 10.0 (q, C-19), 68.7 (t, C-20), 171.4
(s,
HMV CO), 41.0 (t, HMV-CH2), 125.6 (s,
1-HMV), 111.7 (d,
2-HMV), 146.4 (s, 3-HMV), 144.7 (s, 4-HMV), 114.3 (d,
5-HMV),
122.1 (d, 6-HMV), 173.6 (s, PhCH2CO), 41.7 (t,
PhCH2CO),
134.0 (s, i-Ph), 129.0 (d, o-Ph), 128.5 (d,
m-Ph), 127.0 (d, p-Ph),
171.2 (s, Ac), 21.0 (q, Ac), 56.0 (q, OMe). Anal.
(C39H44O11) C,
H.
Phorbol 12-benzoate 13-acetate 20-homovanillate
(6b):
mp 75 C; IR (KBr) 3390, 1720, 1375, 1270, 1150, 785,
710
cm-1; MS (CI, isobutane) m/e 675
(M+ + H) (100); 1H NMR
(300 MHz, CDCl3)
8.03 (d, J = 7.6 Hz,
o-Bz), 7.59 (br s, H-1),
7.58 (t, J = 7.6 Hz, p-Bz), 7.46 (t,
J = 7.6 Hz, m-Bz), 6.79 (br
d, J = 8.0 Hz, 6-HMV), 6.77 (br s, 2-HMV), 6.72 (br d,
J = 8.0
Hz, 5-HMV), 5.66 (d, J = 9.9 Hz, H-12), 5.61 (br s, H-7),
5.56
(br s, OH), 4.54 (d, J = 12.4 Hz, H-20a), 4.47 (d,
J = 12.4 Hz,
H-20b), 3.91 (s, OMe), 3.55 (br s, HMV-CH2),
3.28 (br s, H-8),
3.22 (br s, H-10), 2.48 (d, J = 19.0 Hz, H-5a), 2.33 (d,
J = 19.0
Hz, H-5b), 2.25 (m, H-11), 2.15 (s, Ac), 1, 78 (br s, H-19),
1.35
(s, H-16), 1.20 (s, H-17), 1.01 (d, J = 5.1 Hz, H-14),
0.94 (d, J
= 6.6 Hz, H-18). Anal.
(C38H42O11) C, H.
Phorbol 12-C; IR (KBr) 3400, 2120, 1750,
1375,
1260, 1140, 980, 790 cm-1; 1H NMR (300 Mhz,
CDCl3)
7.53
(br s, H-1), 7.24 (d, J = 8.4 Hz, Ph), 6.98 (d,
J = 8.4 Hz, Ph),
6.79 (br d, J = 8.0 Hz, 6-HMV), 6.77 (s, 2-HMV), 6.71 (d,
J =
8.0 Hz, 5-HMV), 5.52 (br s, H-7), 5.44 (s, OH), 5.38 (d, J
=
10.6 Hz, H-12), 4.49 (d, J = 12.5 Hz, H-20a), 4.41 (d,
J = 12.5
Hz, H-20b), 3.86 (s, OMe), 3.56 (d, J = 15.0 Hz,
PhCH2CO),
3.52 (d, J = 15.0 Hz, PhCH2CO),
3.37 (br d, HMV-CH2), 3.13
(br s, H-8, H-10), 2.39 (d, J = 19.1 Hz, H-5a), 2.28 (d,
J = 19.1
Hz, H-5b), 2.09 (m, H-11), 2.08 (s, Ac), 1.76 (br s, H-19),
1.08
(s, H-16), 1.03 (s, H-17), 0.89 (d, J = 5.1 Hz, H-14),
0.80 (d, J
= 6.6 Hz, H-18); HMRS (FAB+) m/e
calcd for (M+ + 1)
C39H44N3O11 730.2976,
found 730.2985; analytical HPLC (hexane-EtOAc, 1:1) tR = 14.6 min (96%
pure).
Phorbol 12-C; IR (KBr) 3400, 2140, 1720, 1380,
1275,
1180, 1135, 1100 cm-1; MS (CI, isobutane)
m/e 716 (M+ + H)
(100); 1H NMR (300 MHz, CDCl3)
8.01 (d,
J = 8.8 Hz, o-Bz),
7.59 (s, H-1), 7.08 (d, J = 8.8 Hz, m-PH), 6.83
(br d, J = 7.9
Hz, 6-HMV), 6.80 (br s, 2-HMV), 6.76 (br d, J = 7.0
Hz,
5-HMV), 5.64 (d, J = 10.2 Hz, H-12), 5.57 (br s, H-7),
5.53 (br
s, OH), 4.54 (d, J = 12.5 Hz, H-20a), 4.47 (d,
J = 12.5 Hz,
H-20b), 3.90 (s, OMe), 3.40 (HMV-CH2), 3.25 (br
s, H-8), 3.21
(br s, H-10), 2.48 (d, J = 19.1 Hz, H-5a), 2.33 (d,
J = 19.1 Hz,
H-5b), 21.8 (m, H-11), 2.15 (s, Ac), 1.79 (br s, H-19), 1.34
(s,
H-16), 1.20 (s, H-17), 1.00 (d, J = 5.2 Hz, H-14), 0.93
(d, J =
6.6 Hz, H-18); HMRS (FAB+) m/e
calcd for (M+ + 1)
C38H42N3O11
716.2819, found 716.2810; analytical HPLC (hexane-EtOAc,
1:1) tR = 13.8 min (97% pure).
Phorbol 12-cyclohexylacetate 13-acetate 20-homovanillate (6e): mp 70 C; IR (KBr) 3416, 1728, 1516, 1450,
1377,
1253, 1149, 987 cm-1; MS (CI, isobutane)
m/e 695 (M+ + H)
(100); 1H NMR (300 MHz, CDCl3)
7.57 (br s,
H-1), 6.82 (br
d, J = 8.0 Hz, 6-HMV), 6.79 (br s, 2-HMV), 6.73 (br d,
J = 8.0
Hz, 5-HMV), 5.57 (br s, H-7), 5.40 (d, J = 10.4 Hz, H-12),
4.49
(d, J = 12.5 Hz, H-20a), 4.45 (d, J = 12.5
Hz, H-20b), 3.88 (s,
OMe), 3.70 (d, J = 14.5 Hz,
HMV-CH2), 3.57 (d, J = 14.5
Hz,
HMV-CH2), 3.15 (br s, H-8, H-10), 2.43 (d,
J = 19.0 Hz, H-5a),
2.30 (d, J = 19.0 Hz, H-5b), 2.17 (br s,
C6H11-CH2CO),
2.09
(m, H-11), 2.09 (s, Ac), 1.78 (br s, H-19), 1.70-1.30 (m,
C6H11-CH2CO), 1.21 (s, H-16), 1.17 (s, H-17), 0.93 (d,
J = 5.2 Hz,
H-14), 0.83 (d, J = 6.6 Hz, H-18); 13C NMR (75
MHz, CDCl3)
160.7 (d, C-1), 135.2 (s, C-2), 208.5 (s, C-3), 73.5 (s,
C-4),
38.7 (t, C-5), 132.8 (s, C-6), 132.0 (d, C-7), 39.2 (d, C-8),
78.0
(s, C-9), 56.0 (s, C-10), 42.7 (d, C-11), 76.2 (d, C-12), 65.5
(s,
C-13), 35.9 (d, C-14), 25.4 (s, C-15), 23.6 (q, C-16), 16.7
(q,
C-17), 14.3 (q, C-18), 10.0 (q, C-19), 68.8 (t, C-20), 171.0
(s,
HMV-CO), 41.0 (t, HMV-CH2), 152.6 (s,
1-HMV), 111.7 (d,
2-HMV), 144.2 (s, 3-HMV), 146.5 (s, 4-HMV), 114.3 (d,
5-HMV),
122.1 (d, 6-HMV), 56.0 (q, OMe), 172.9 (s,
C6H11-CH2CO),
42.4
(t, C6H11-CH2CO), 35.2
(d,
C6H11-CH2CO),
32.9 (t,
C6H11-CH2CO), 26.0 (t,
C6H11-CH2CO),
26.0 (t,
C6H11-CH2CO),
173.7 (s,
Ac), 21.0 (q, Ac); HMRS (FAB+) m/e
calcd for (M+ + 1)
C39H51O11 695.3431, found 695.3437;
analytical HPLC (hexane-EtOAc, 1:1) tR = 15.2 min (99%
pure).
Phorbol 12-cyclohexanecarboxylate 13-acetate 20-homovanillate (6f): mp 68 C; IR (KBr) 3400, 1725, 1630,
1516,
1377, 1273, 1263, 1130, 1034 cm-1; MS (CI, isobutane)
m/e 681
(M+ + H) (100); 1H NMR (300 MHz,
CDCl3)
7.56 (s, H-1),
6.81 (d, J = 8.0 Hz, 6-HMV), 6.78 (br s, 2-HMV), 6.73 (br
d, J
= 8.0 Hz, 5-HMV), 5.56 (br s, H-7), 5.53 (br s, OH), 5.49 (br
s,
OH), 5.37 (d, J = 10.6 Hz, H-12), 4.49 (d, J
= 12.7 Hz, H-20a),
4.45 (d, J = 12.7 Hz, H-20b), 3.88 (s, OMe), 3.73 (d,
J = 15.0
Hz, HMV-CH2), 3.53 (d, J = 15.0 Hz,
HMV-CH2), 3.15 (br s,
H-8, H-10), 2.43 (d, J = 19.0 Hz, H-5a), 2.33 (m,
C6H11-CO),
2.30 (d, J = 19 Hz, H-5b),
2.09 (s, Ac), 2.08 (m, H-11), 1.87 (m,
C6H11-CO), 1.79 (br s,
H-19), 1.70 (m,
C6H11-CO), 1.45
(m,
C6H11-CO), 1.30 (m,
C6H11-CO), 1.21 (s,
H-16), 1.17 (s, H-17),
0.93 (d, J = 5.4 Hz, H-14), 0.85 (d, J = 6.6
Hz, H-18); 13C NMR
(75 MHz, CDCl3)
160.0 (d, C-1), 135.2 (s,
C-2), 208.6 (s, C-3),
73.5 (s, C-4), 38.7 (t, C-5), 132.8 (s, C-6), 132.1 (d, C-7),
39.2
(d, C-8), 78.1 (s, C-9), 56.0 (d, C-10), 42.9 (d, C-11), 76.3
(d,
C-12), 65.5 (s, C-13), 36.0 (d, C-14), 25.5 (s, C-15), 23.8 (q,
C-16),
16.9 (q, C-17), 14.4 (q, C-18), 10.1 (q, C-19), 68.9 (t, C-20),
171.4
(s, HMV-CO), 41.1 (t, HMV-CH2), 125.6
(s, 1-HMV), 111.7 (d,
2-HMV), 146.5 (s, 3-HMV), 144.7 (s, 4-HMV), 114.3 (d,
5-HMV),
122.2 (d, 6-HMV), 56.0 (q, OMe), 175.8 (s,
C5H11CO), 43.3 (d,
C6H11CO), 29.1 (t,
C6H11CO), 28.9 (t,
C6H11CO), 25.4 (t,
C6H11CO), 25.3 (t,
C6H11CO), 25.8 (t,
C6H11CO), 173.8 (s, Ac),
21.2
(q, Ac); HMRS (FAB+) m/e calcd for
(M+ + 1)
C38H49O11
681.3275, found 681.3288; analytical HPLC (hexane-EtOAc,
4:6) tR = 12.9 min (98% pure).
Attempted Synthesis of Phorbol 12-Acetate
13-Phenylacetate 20-Trityl Ether. (a) To a solution of phorbol
20-trityl ether (1.0 g, 1.65 mmol) in dry
CH2Cl2 (45 mL) were
added DCC (340 mg, 1.65 mmol, 1 equiv), phenylacetic acid
(225 mg, 1.65 mmol, 1 equiv), and DMAP (15 mg). After
stirring for 30 min under a nitrogen atmosphere, the
reaction
mixture was worked up by dilution with ether (ca. 40 mL)
and
filtration. The filtrate was evaporated, and the residue
was
purified by column chromatography (hexane-EtOAc, 7:3) to
give 415 mg (33%) of phorbol 13-phenylacetate 20-trityl
ether
(4b) as a powder: mp 95 C; IR (KBr) 3430, 1709, 1448,
1269,
1159, 1030, 702 cm-1; MS (CI, isobutane)
m/e 725 (M+ + H)
(100); 1H NMR (300 MHz, CDCl3)
7.55 (s,
H-1), 7.44-7.20
(aromatics), 5.56 (br s, H-7), 3.92 (d, J = 10.0 Hz,
H-12), 3.69
(br s, H-20a,b), 3.55 (br s, OH), 3.07 (br s, H-8), 3.02 (br
s,
H-10), 2.46 (br d, J = 19.1 Hz, H-5a), 2.38 (br d,
J = 191.1 Hz,
H-5b), 1.78 (br s, H-19), 1.23 (s, H-16), 1.09 (s, H-17), 1.04
(d,
J = 6.2 Hz, H-18), 0.94 (d, J = 5.1 Hz,
H-14).
(b) To a solution of 4b (134 mg, 0.18 mmol) in dry
CH2Cl2
(3 mL) were added glacial acetic acid (20.6 L, 21.8 mg,
0.36
mmol, 2 equiv), DCC (74.3 mg, 0.36 mL, 2 equiv), and DMAP
(10 mg). After stirring for 3 h at room temperature,
the
reaction mixture was worked up by dilution with ether (ca.
3
mL) and filtered. The filtrate was evaporated and the
residue
purified by HPLC (hexane-EtOAc, 7:3) to give 42 mg
(30%)
of phorbol 12-phenylacetate 13-acetate (8a) (identified
by
comparison of the 1H NMR and IR spectra with an
authentic
sample prepared from 4a) and 20 mg (15%) of
phorbol
12-phenylacetate 20-trityl ether (8b). 8a:
foam; IR (KBr) 3400,
1720, 1450, 1380, 1260, 980, 705 cm-1; MS (CI, isobutane)
m/e
767 (M+ + H) (90); 1H NMR (300 MHz,
CDCl3)
7.57 (br s,
H-1), 7.43-7.21 (aromatic, 20 H), 5.61 (br s, H-7), 5.42 (d,
J =
11.5 Hz, H-12), 3.66 (d, J = 14.2 Hz,
Ph-CH2CO), 3.63 (d, J
=
14.2 Hz, Ph-CH2CO), 3.51 (br s, H-20a,b), 3.24
(br s, H-10),
3.11 (br s, H-8), 2.46 (d, J = 18.9 Hz, H-5a), 2.40 (d,
J = 18.9
Hz, H-5b), 2.05 (s, Ac), 1.72 (br s, H-19), 1.10 (s, H-16),
1.03
(s, H-17), 0.84 (d, J = 6.4 Hz, H-18).
8b: powder; mp 96-98 C; MS (CI, isobutane)
m/e 707 (M+
+ H - H2O) (100); 1H NMR (300 MHz,
CDCl3)
7.56 (br s,
H-1), 7.43-7.21 (m, aromatics, 20 H), 5.58 (br d, J =
5.8 Hz,
H-7), 5.45 (d, J = 10.3 Hz, H-12), 5.35 (s, OH), 3.65 (br
s,
H-20a,b), 3.22 (br s, H-8), 3.08 (br s, H-10), 2.48 (d, J
= 19.0
Hz, H-5a), 2.40 (d, J = 19.0 Hz, H-5b), 2.06 (m, H-11),
1.76
(br s, H-19), 0.97 (s, H-16), 0.88 (s, H-17), 0.83 (d, J =
6.2 Hz,
H-18).
Phorbol 12,13-Bis(phenylacetate)
20-Homovanillate
(10). (a) To a solution of phorbol 20-trityl ether (210 mg,
0.34
mmol) in dry CH2Cl2 (10 mL) were added
pyridine (117 L,
109 mg, 1.36 mmol, 4 equiv) and phenylacetyl chloride (183
L, 214 mg, 1.36 mmol, 4 equiv). After stirring for 1 h at
room
temperature, the reaction mixture was worked up by
addition
of water, and the organic phase was washed with dilute
HCl,
saturated NaHCO3, and brine. After drying
(Na2SO4) and
removal of the solvent, the residue was purified by column
chromatography (10 g of silica gel, hexane-EtOAc, 8:2,
as
eluant) to give 258 mg (90%) of phorbol
12,13-bis(phenylacetate) 20-trityl ether (9) as a powder: mp 54-56
C;
IR (KBr)
3416, 1713, 1497, 1267, 1151, 707 cm-1; MS (CI,
isobutane)
m/e 843 (M+ + H) (25);
1H NMR (300 MHz, CDCl3)
7.59
(br
s, H-1), 7.43-7.25 (m, aromatics, 25 H), 5.58 (d, J =
5.4 Hz,
H-7), 5.40 (d, J = 10.6 Hz, H-12), 5.36 (br s, OH), 5.26
(br s,
OH), 3.66 (br m, 2 × Ph-CH2CO), 3.49 (br s,
H-20a, b), 3.22
(br s, H-10), 3.09 (br s, H-8), 2.41 (d, J = 19.0 Hz,
H-5a), 2.37
(d, J = 19.0 Hz, H-5b), 2.06 (m, H-11), 1.77 (br s, H-19),
0.98
(s, H-16), 0.89 (s, H-17), 0.86 (d, J = 6.2 Hz,
H-18).
(b) Conversion of 9 to 10 was carried out
according to the
general procedure employed for the synthesis of 6a.
10 was
obtained as a white powder: mp 64 C; 1H NMR (300
MHz,
CDCl3)
7.54 (br s, H-1), 7.35-7.25 (m, 2 ×
Ph-CH2CO), 6.86
(d, J = 8.0 Hz, 6-HMV), 6.78 (br s, 2-HMV), 6.71 (br d,
J = 8.0
Hz, 5-HMV), 5.52 (br d, J = 4.0 Hz, H-7), 5.44 (d,
J = 10.4 Hz,
H-12), 5.39 (s, OH), 4.48 (d, J = 12.8 Hz, H-20a), 4.41
(d, J =
12.8 Hz, H-20b), 3.89 (s, OMe), 3.65 (m, 2 ×
Ph-CH2CO), 3.51
(s, HMV-CH2), 3.11 (br s, H-8, H-10), 2.41 (d,
J = 18.9 Hz,
H-5a), 2.28 (d, J = 18.9 Hz, H-5b), 1.77 (br s, H-19),
0.94 (s,
H-16), 0.87 (s, H-17), 0.83 (d, J = 6.1 Hz, H-18); HMRS
(FAB+)
m/e calcd for (M+ + 1)
C45H49O11 765.3275, found
765.3282;
analytical HPLC (hexane-EtOAc, 4:6) tR =
10.2 min (99%
pure).
12-Dehydrophorbol 13-Acetate 20-Homovanillate
(12a).
(a) To a solution of phorbol 13-acetate 20-trityl ether
(4a) (1.06
g, 1.60.4 mmol) in dry CH2Cl2 (26 mL) were
added pyridinium
chlorochromate (PCC; 1.77 g, 8.2 mmol, 5 equiv) and
powdered
molecular sieves (4 Å, 1.37 g). After stirring at room
temperature for 3 h, the reaction mixture was worked up by the
addition of ether (ca. 60 mL) and filtration through
Celite.
After removal of the solvent, the residue was purified
by
column chromatography (hexane-EtOAc, 7:3) to give 703 mg
(67%) of the 13-dehydro derivative as a white powder:
mp
120-123 C; IR (KBr) 3420, 1730, 1700, 1445, 1375, 1260,
760,
700 cm-1; MS (CI, isobutane); m/e
647 (M+ + H) (60); 1H NMR
(300 MHz, CDCl3)
7.56 (br s, H-1), 7.45-7.22
(aromatic, 15
H), 5.76 (br d, J = 5.0 Hz, H-7), 5.40 (br s, OH), 3.55
(br s,
H-20a,b), 3.24 (br s, H-8, H-10), 2.94 (q, J = 6.4 Hz,
H-11),
2.61 (d, J = 18.5 Hz, H-5a), 2.43 (d, J =
18.5 Hz, H-5b), 2.17
(s, Ac), 1.78 (br s, H-19), 1.49 (d, J = 4.9 Hz, H-14),
1.37 (s,
H-16), 1.23 (s, H-17), 1.19 (d, J = 6.4 Hz,
H-18).
(b) The conversion of 12-dehydrophorbol 13-acetate
20-trityl
ether to 12a was carried out according to the general
procedure
used for the synthesis of 6a. 12a was
obtained as a white
powder: mp 120 C; IR (KBr) 3410, 1732, 1701, 1516,
1271,
1255, 1147 cm-1; 1H NMR (300 MHz,
CDCl3)
7.49 (br s, H-1),
6.81 (br d, J = 8.0 Hz, 6-HMV), 6.78 (br s, 2-HMV), 6.46
(br d,
J = 8.0 Hz, 5-HMV), 5.66 (br s, OH), 5.57 (br s, H-7),
5.43 (br
s, OH), 4.54 (d, J = 12.7 Hz, H-20a), 4.46 (d,
J = 12.7 Hz,
H-20b), 3.87 (s, OMe), 3.53 (br s, HMV-CH2),
3.13 (br s, H-10),
2.87 (q, J = 6.4 Hz, H-11), 2.87 (br s, H-8), 2.51 (br d,
J = 19.0
Hz, H-5a), 2.34 (br d, J = 19.0 Hz, H-5b), 2.17 (s, Ac),
1.78 (br
s, H-19), 1.32 (s, H-16), 1.18 (s, H-17), 1.15 (d, J = 6.4
Hz,
H-18); HMRS (FAB+) m/e calcd for
(M+ + 1)
C31H37O10
569.2387, found 569.2374; analytical HPLC (hexane-EtOAc,
1:1) tR = 14.1 min (98.5% pure).
12-Dehydrophorbol 13-Phenylacetate 20-Homovanillate (12b). Phorbol 13-phenylacetate 20-trityl ether
(4b) was
oxidized as described above for 4a. The 12-dehydro
derivative
was obtained as a colorless foam: MS (CI, isobutane)
m/e 723
(M+ + H) (100); 1H NMR (300 MHz,
CDCl3) 7.52 (br s, H-1),
7.45-7.19 (aromatics, 20 H), 5.67 (br s, H-7), 5.34 (br s,
OH),
3.76 (Ph-CH2CO), 3.53 (br s, H-20a,b), 3.22 (br
s, H-8, H-10),
2.96 (q, J = 6.4 Hz, H-11), 2.52 (d, J = 19.0
Hz, H-5a), 2.46 (d,
J = 19.0 Hz, H-5b), 1.78 (br s, H-19), 1.31 (s, H-16),
1.28 (s,
H-17), 1.16 (d, J = 6.4 Hz, H-18).
Conversion of 12b was carried out according to the
general
procedure described for the synthesis of 6a.
12b was obtained
as a powder: mp 120 C; IR (KBr) 3410, 1730, 1698,
1516,
1273, 1234, 1151 cm-1; 1H NMR
(CDCl3, 300 MHz)
7.49 (br
s, H-1), 7.36-7.29 (Ph-CH2CO), 6.85 (br
d, J = 8.0 Hz, 6-HMV),
6.78 (br s, 2-HMV), 6.70 (br d, J = 8.0 Hz, 5-HMV), 5.64
(br s,
OH), 5.55 (br s, H-7), 5.37 (br s, OH), 4.52 (d, J = 12.6
Hz,
H-20a), 4.44 (d, J = 12.6 Hz, H-20b), 3.84 (s, OMe), 3.75
(br s,
Ph-CH2CO), 3.52 (s,
HMV-CH2), 3.12 (br s, H-10), 2.86 (q,
J =
6.4 Hz, H-11), 2.86 (br s, H-8), 2.49 (d, J = 19.0 Hz,
H-5a),
2.32 (d, J = 19.0 Hz, H-5b), 1.79 (br s, H-19), 1.20 (s,
H-16),
1.17 (s, H-17), 1.15 (d, J = 6.4 Hz, H-18): HMRS
(FAB+) m/e
calcd for (M+ + 1)
C37H41O10 645.2700, found
645.2709;
analytical HPLC (hexane-EtOAc, 1:1) tR = 9.6
min (99% pure).
(3 7.30 (m,
Ph-CH2CO), 6.81 (br d, J = 8.0
Hz,
6-HMV), 6.78 (br s, 2-HMV), 6.77 (br d, J = 8.0 Hz,
5-HMV),
5.75 (br s, H-1), 5.57 (br s, H-7), 5.56 (br s, OH), 5.34
(d, J =
10.2 Hz, H-12), 4.48 (d, J = 12.2 Hz, H-20a), 4.45 (d,
J = 12.2
Hz, H-20b), 3.88 (s, OMe), 3.65 (br s,
Ph-CH2CO), 3.54 (s,
HMV-CH2), 2.67 (br s, H-8), 3.12 (m, H-10), 2.66
(d, J = 19.3
Hz, H-5a), 2.38 (d, J = 19.3 Hz, H-5b), 2.07 (s, Ac), 1.67
(br s,
H-19), 1.09 (s, H-16), 1.01 (s, H-17), 0.89 (d, J = 6.4
Hz, H-18);
HMRS (FAB+) m/e calcd for
(M+ + 1) C39H47O11
691.3118,
found 691.3125; analytical HPLC (hexane-EtOAc, 1:1)
tR =
12.9 min (96% pure). The stereochemistry of the
3-hydroxyl
was assigned by analogy with the results reported for
other
phorbol esters.40
Phorbol 12-Phenylacetate 13-Acetate 20-Acetylhomovanillate (14). To a solution of phorbol 12-phenylacetate
13-acetate (5a) (100 mg, 0.19 mmol) in dry
CH2Cl2 (5 mL) were
added acetylhomovanillic acid33 (0.38 mmol, 2 equiv) and
DCC
(79 mg, 0.38 mmol, 2 equiv). After stirring for 1 h at
room
temperature, the reaction mixture was worked up by
dilution
with ether (10 mL) and filtered. The filtrate was
evaporated
and the residue purified by column chromatography (5 g of
silica gel, hexane-EtOAc, 6:4, as eluant) to give 125 mg
(90%)
of 14: mp 92-95 C; IR (KBr) 3412, 1767, 1735, 1263,
1198,
1152, 984 cm-1; 1H NMR (300 MHz,
CDCl3)
7.53 (br s, H-1),
7.30 (m, Ph-CH2CO), 6.97 (br d,
J = 8.0 Hz, 6-HMV), 6.90 (br
s, 2-HMV), 6.84 (br d, J = 8.0 Hz, 5-HMV), 5.61 (br s,
H-7),
5.46 (br s, OH), 5.40 (d, J = 10.5 Hz, H-12), 4.52 (d,
J = 12.4
Hz, H-20a), 4.45 (d, J = 12.4 Hz, H-20b), 3.84 (s, OMe),
3.65
(d, J = 14.9 Hz, Ph-CH2CO), 3.62
(d, J = 14.9 Hz,
Ph-CH2CO),
3.59 (s, HMV-CH2), 3.14 (br s, H-8, H-10), 2.36
(d, J = 19.0
Hz, H-5a), 2.30 (s, Ac), 2.28 (d, J = 19.0 Hz, H-5b), 2.08
(m,
H-11), 2.08 (s, Ac), 1.77 (br s, H-19), 1.08 (s, H-16), 0.99
(s,
H-17), 0.96 (d, J = 5.0 Hz, H-14), 0.88 (d, J
= 6.4 Hz, H-18);
HMRS (FAB+) m/e calcd for
(M+ +1) C41H47O12
731.3067, found
731.3077; analytical HPLC (hexane-EtOAc, 7:3)
tR = 9.9 min
(99% pure).
Biological Evaluation. Radioligand Binding
Studies.
Binding assays using rat spinal cord, rat urinary
bladder,
porcine dorsal horn, and human dorsal horn (obtained
post-mortem) membranes were performed as described previously.20,21 Briefly, tissues were disrupted
with the aid of a
Polytron tissue homogenizer in ice-cold buffer A (pH 7.4),
containing (in mM) NaCl, 5.8; KCl, 5; CaCl2, 0.75;
MgCl2, 2;
sucrose, 137; and HEPES, 10. Tissue homogenates were
first
centrifuged for 10 min at 1000g (4 C), and then the
resulting
supernatants were further centrifuged for 30 min at
35000g
(4
C). The pellets from the second centrifugation
resuspended
in buffer A were aliquoted and then kept at -80
C
until
assayed. For competition studies, 50
g protein aliquots
of
rat spinal cord membranes were incubated in triplicate
with
20 pM [3H]RTX, the appropriate
Kd from the saturation
experiments, in 500
L of buffer A containing 0.25 mg/mL
bovine serum albumin (Cohn fraction V) in the absence or
presence of 100 nM nonradioactive RTX. In this way,
nonspecific binding could be determined. Competing
ligands
(dissolved in ethanol and then diluted in buffer A
containing
10 mg/mL bovine serum albumin) were added using 1:3
dilutions; the final concentration of the organic solvents in
the
assay mixture never exceeded 0.1% (v/v) and did not have
any
measurable effect on specific RTX binding. For the
determination of RTX binding curves in the presence of competing
ligands, membranes were incubated with increasing concentrations (6-400 pM) of [3H]RTX in the absence or
presence of
the concentration of the test compounds which inhibited
RTX
binding by 50% in the competition experiments. The
binding
reaction was initiated by transferring the assay tubes into
a
shaking water bath (37
C) and then terminated following
a
60 min incubation by cooling the assay mixtures on ice.
Nonspecific binding was then reduced by adding 100
g
of
bovine
1-acid glycoprotein (AGP; Sigma, St. Louis, MO)
to
each tube.41 AGP works by sequestering free
[3H]RTX which
is in equilibrium with nonspecifically bound
[3H]RTX.41 Since
the off-rate of receptor-bound RTX is unmeasurably slow at
0
C, addition of AGP does not compromise specific RTX
binding.39 Bound and free [3H]RTX were
separated by pelleting
the membranes in a Beckman 12 microfuge (maximal velocity,
15 min) and then quantitated by scintillation counting.
Binding data were analyzed either by the collection of computer
programs of PcPherson, collectively referred to as KELL
(Biosoft, Cambridge, U.K.), or by a computer program which
fits the allosteric Hill equation to the measured values
(FitP,
Biosoft).21
Determination of
In other experiments, capsaicin and 6a (up to 10 mg/ear) dissolved in acetone were applied on the inner surface of rat ear; animals were kept under surveillance for a period of 6 h to detect erythema (ear reddening).
To examine the acute hypothermic action of vanilloids,
rectal
temperature of rats habituated to room temperature (20
C)
was determined using a small animal temperature probe
(introduced into a depth of 5 cm) as described by Szikszay
et
al.,43 both before and 60 min after vanilloid treatment.
For
vanilloid treatment, compounds dissolved in ethanol were
injected sc into the scruff of the neck of the animals in a
volume
of 100
L under light ether anesthesia in the following
dose
ranges: RTX, from 10-7 to 10-4 g/kg;
capsaicin, from 10-4 to
10-2 g/kg; PPAHV (6a) from 1 to 200 mg/kg.
After the
measurement of hypothermic effect had been completed,
animals injected with 1, 10, and 100 mg/kg PPAHV, respectively, were randomly distributed into two groups (five
animals
each): In the first group, animals were challenged the
day
after with 5
g/ear RTX applied topically on the inner
surface
of the rat ear; animals were killed by cervical dislocation
30
min later, and a 0.5 cm diameter ear plug was removed and
weighed to quantify edema formation.44 Rats belonging
to the
second group were sacrificed under CO2 anesthesia 24 h
after
treatment, the spinal cord was removed, and membranes were
prepared for [3H]RTX binding experiments in order to
determine vanilloid receptor loss.45 Whenever possible,
animal
experimentation was carried out under light ether
anesthesia
to avoid any unncessary discomfort to the rats. All
protocols
were approved by the institutional ethics committee.
We are very grateful to Dr. B. Sorg (Deutsches Krebsforschung Zentrum, Heidelberg, Germany) for precious advice on the large-scale isolation of phorbol and for providing authentic samples of phorbol and phorbol 13-acetate 20-trityl ether. This work was supported by the MURST (fondi 60%), the Swedish Medical Research Council, and the Magnus Bergvalls Stiftelse.
* In papers with more than one author, the asterisk indicates the name of the author to whom inquiries about the paper should be addressed.
Abstract published in Advance ACS
Abstracts, July 1, 1996.
1. Buck, S. H.; Burks, T. F. The Neuropharmacology of
Capsaicin:
a Review of Some Recent Observations. Pharmacol.
Rev. 1986,
38, 179-226.
2. Holzer, P. Capsaicin: Cellular targets, Mechanisms of
Action,
and Selectivity for the Thin Sensory Neurons.
Pharmacol. Rev.
1991, 43, 144-201.
3. Bevan, S.; Docherty, R. J. Cellular Mechanism of Action of Capsaicin. In Capsaicin in the Study of Pain; Wood, J. N., Ed.; Academic Press: London, 1993; pp 27-44.
4. Rumsfield, J. A.; West, D. P. Topical Capsaicin in
Dermatological
and Peripherical Pain Disorders. DICP Ann.
Pharmacother.
1991, 25, 381-387.
5. Szolcsanyi, J. Perspectives of Capsaicin-type Agents in Pain Therapy and Research. In Contemporary Issues in Chronic Pain Management; Parris, W. C. V., Ed.; Kluwer Academic: Boston, 1991; pp 97-124.
6. Campbell, E.; Bevan, S.; Dray, A. Clinical Applications of Capsaicin and its Analogues. In Capsaicin in the Study of Pain; Wood, J. N., Ed.; Academic Press: London, 1993; pp 255-272.
7. Szolcsanyi, J.; Jancso-Gabor, A. Sensory Effects of
Capsaicin
Congeners. II. Importance of Chemical Structure and
Pungency
in Desensitizing Activity of Capsaicin-type Compounds.
Drug
Res. 1976, 26, 33-37.
8. Hayes, A. G.; Oxford, A.; Reynolds, M.; Shingler, A. H.;
Skingle,
M.; Smith, C.; Tyers, M. B. The Effect of a Series of
Capsaicin
Analogs on Nociception and Body Temperature in the Rat.
Life
Sci. 1984, 34, 1241-1248.
9. Brand, L.; Berman, E.; Schwen, R.; Loomans, M.; Janusz,
J.;
Bohne, R.; Maddin, C.; Gardner, J.; LaHann, T.; Farmer,
R.;
Jones, L.; Chiabrando, C.; Fanelli, R. NE-19550: A Novel,
Orally
Active Anti-inflammatory Analgesic. Drug Exp.
Clin. Res. 1987,
13, 259-265.
10. Janusz, J. M.; Buckwalter, B. L.; Young, P. A.; LaHann, T.
R.;
Farmer, R. W.; Kasting, G. B.; Loomans, M. E.; Kerchkaert,
G.
A.; Maddin, C. S.; Berman, E. F.; Bohne, R. L.; Cupps, T.
L.;
Milstein, J. R. Vanilloids. 1. Analogs of Capsaicin with
Antinociceptive and Antiinflammatory Activity. J.
Med. Chem. 1993,
36, 2595-2604.
11. Walpole, C. S. J.; Wrigglesworth, R.; Bevan, S.; Campbell,
E.
A.; Dray, A.; James, I. F.; Perkins, M. N.; Reid, D. J.; Winter,
J.
Analogues of Capsaicin with Agonist Activity as Novel
Analgesic
Agents; Structure-activity Studies. 1. The Aromatic
"A-Region".
J. Med. Chem. 1993,
36, 2362-2372.
12. Walpole, C. S. J.; Wrigglesworth, R.; Bevan, S.; Campbell,
E.
A.; Dray, A.; James, I. F.; Masdin, K. J.; Perkins, M. N.;
Winter,
J. Analogues of Capsaicin with Agonist Activity as Novel
Analgesic Agents; Structure-activity Studies 2. The Amide
Bond
"B-Region". J. Med. Chem.
1993, 36, 2373-2380.
13. Walpole, C. S. J.; Wriggleworth, R.; Bevan, S.; Campbell, E.
A.;
Dray, A.; James, I. F.; Masdin, K. J.; Perkins, M. N.; Winter,
J.
Analogues of Capsaicin with Agonist Activity asNovel
Analgesic
Agents; Structure-Activity Studies. 3. The Hydrophobic
Side-chain "C-Region". J. Med.
Chem. 1993, 36,
2381-2389.
14. Szallasi, A.; Blumberg, P. M. Resiniferatoxin, a
Phorbol-Related
Diterpene Acts as an Ultrapotent Analog of Capsaicin, the
Irritant Constituent in Red Pepper. Neuroscience
1989, 30,
515-520.
15. Blumberg, P. M.; Szallasi, A.; Acs, G. Resiniferatoxin, an Ultrapotent Capsaicin Analogue. In Capsaicin in the Study of Pain; Wood, J. N., Ed.; Academic Press: London, 1993; pp 45-62.
16. Bevan, S.; Hothi, S.; Hughes, G.; James, I. F.; Rang, H. P.;
Shah,
K.; Walpole, C. S. J.; Yeats, J. C. Capsazepine: a
Competitive
Antagonist of the Sensory Neurone Excitant Capsaicin.
Br. J.
Pharmacol. 1992, 107,
544-552.
17. ZurHausen, H.; Bornkamm, G. W.; Schmidt, R. J.; Hecker, E.
Tumor Initiators and Promoters in the Induction of Epstein-Barr Virus. Proc. Natl. Acad.
Sci. U.S.A.
1979, 76, 782-785.
18. Szallasi, A.; Blumberg, P. M. Resiniferatoxin and its
Analogs
Provide Novel Insights into the Pharmacology of the
Vanilloid
(Capsaicin) Receptor. Life Sci. 1990,
47, 1399-1408.
19. Szallasi, A.; Blumberg, P. M. Specific Binding of
Resiniferatoxin,
an Ultrapotent Capsaicin Ansalog, by Dorsal Root Ganglion
Membranes. Brain Res. 1990, 524,
106-111.
20. Szallasi, A. Autoradiographic Visualization and
Pharmacological
Characterization of Vanilloid (Capsaicin) Receptors in
Several
Species, Including Man. Acta Physiol. Scand.
1995, 155 (Suppl.
629), 1-68.
21. Szallasi, A.; Lewin, N. E.; Blumberg, P. M. Vanilloid
(Capsaicin)
Receptor in the Rat: Positive Cooperativity of
Resiniferatoxin
Binding and its Modulation by Reduction and Oxidation.
J.
Pharmacol. Exp. Ther. 1993,
266, 678-683.
22. Maderspach, K.; Fajszi, C. -Adrenergic Receptors of Brain
Cells.
Membrane Integrity Implies Apparent Positive
Cooperativity
and Higher Affinity. Biochim. Biophys.
Acta 1982, 692, 469-478.
23. Acs, G.; Lee, J.; Marquez, V.; Blumberg, P. M. Vanilloid
Receptors: Distinct Structure-activity Relations for
Simulation
of 45Ca Uptake and for High Affinity Binding in
Cultured Rat
Dorsal Root Ganglion Neurons and Dorsal Root Ganglion
Membranes. Mol. Brain Res. 1996,
35, 173-185.
24. Lee, J.; Acs, G.; Blumberg, P. M.; Marquez, V. E. Thiourea
Analogues of Resiniferatoxin as Ligands for the Vanilloid
Receptor. Bioorg. Med. Chem.
Lett. 1995, 5,
1331-1334.
25. Acs, G.; Lee, J.; Marquez, V. E.; Wang, S.; Milne, G. W.; Du,
L.;
Lewin, N. E.; Blumberg, P. M. Resiniferatoxin amide and
Analogues as Ligands for Protein Kinase C and Vanilloid
Receptors and Determination of Their Biological Activities
as
Vanilloids. J. Neurochem. 1995,
65, 301-308.
26. Szallasi, A.; Blumberg, P. M. Mechanism and Therapeutic
Potential of Vanilloids (Capsaicin-like Molecules).
Adv. Pharmacol. 1993, 24, 123-155.
27. Bloomfield, G. C.; Wrigglesworth, R.; Ritchie, T. J. Synthesis
of
2,9,10-Trioxatricyclo[4.3.1.03,8]decane
Analogues of Resiniferatoxin. J. Chem. Soc., Perkin
Trans. 1 1992, 1229-1236.
28. Szallasi, A.; Sharkey, N. A.; Blumberg, P. M.
Structure-activity
Analysis of Resiniferatoxin Analogs. Phytother.
Res. 1989, 3,
253-257.
29. Hecker, E.; Schmidt, R. Phorbolesters, the Irritant Cocarcinogens of Croton Tiglium L. In Progress in the Chemistry of Organic Natural Products; Herz, W., Grisebach, H., Kirby, G. W., Eds.; Springer: Wien, 1974; Vol. 31, pp 377-467.
30. Blumberg, P. M. Class of Compounds Having a Variable Spectrum of Activities for Capsaicin-Like Responses, Composition and use Thereof. U.S. Patent 5,021,450, 1991.
31. Sorg, B.; Fürstenberger, G.; Berry, D. L.; Hecker, E.; Marks,
F.
Preparation of Retinoic Acid Esters of Phorbol Derivatives.
J.
Lipid Res. 1982, 23,
443-447.
32. Luche, J.-L.; Gemal, A. L. Lanthanides in Organic Synthesis.
6.
The Reduction of -Enones by Borohydride in the Presence
of
Lanthanoid Chlorides: Synthetic and Mechanistic Aspects.
J.
Am. Chem. Soc. 1981,
103, 5454-5459.
33. Fisher, H. E.; Hibbert, H. Studies on Lignin and Related
Compounds. LXXXIII. Synthesis of
3-Hydroxy-1-(4-hydroxy-3-methoxyphenyl)-2-propanone. J. Am.
Chem. Soc. 1947,
69,
1208-1210.
34. Szallasi, A.; Acs, G.; Cravotto, G.; Blumberg, P. M.;
Lundberg,
J. M.; Appendino, G. A Novel Agonist, PPAHV, Abolishes
Positive Cooperativity of Binding by the Vanilloid Receptor.
Eur.
J. Pharmacol. 1996, 299,
221-228.
35. (a) Goso, C.; Piovacari, G.; Szallasi, A.
Resiniferatoxin-Induced
Loss of Vanilloid Receptors is Reversible in the Urinary
Bladder
but not in the Spinal Cord of the Rat. Neurosci.
Lett. 1993, 162,
197-200.
36. In all natural 12,13-phorbol diesters where one of the acyl residues is acetic acid and the other an aromatic ester group, the acetate is always bound to the C-13 oxygen (Evans, F. J.; Taylor, S. E. Pro-Inflammatory, Tumor-Promoting and Anti-Tumor Diterpenes of the Plant Families Euphorbiaceae and Thymelaeaceae. In Progress in the Chemistry of Organic Natural Products; Herz, W., Grisebach, H., Kirby, G. W., Eds.; Springer: Wien, 1983; Vol. 44, pp 1-99), suggesting an inherent bias for this arrangement. The alternative arrangement (12-acetyl, 13-acyl) is known with linear aliphatic acids.29
37. Koshland, D. E.; Nemethy, G.; Filmer, D. Comparison of
Experimental Binding Data and Theoretical Models in
Protein
Containing Subunits. Biochemistry
(Washington, DC) 1966,
5,
365-385.
38. Schmidt, R. J.; Evans, F. J. Investigation into the
Skin-irritant
Properties of Resiniferonol Ortho Esters. Inflammation
1979,
3, 173-280.
39. James, I. F.; Walpole, C. S. J.; Szallasi, A. Unpublished observations.
40. Wender, P. A.; Irie, K.; Miller, B. L. Synthesis and Binding
of
Photoaffinity Ligand Candidates for Protein Kinase C.
J. Org.
Chem. 1993, 58,
4179-4181.
41. Szallasi, A.; Lewin, N. E.; Blumberg, P. M. Identification of
1-Acid Glycoprotein (Orsomucoid) as a Major Vanilloid-binding
Protein in Serum. J. Pharmacol.
Exp. Ther. 1992, 262,
883-888.
42. Jancso, N.; Jancso-Gabor, A.; Takats, J. Pain and
Inflammation
Induced by Nicotine, Acetylcholine and
Structurally-related
Compounds and Their Prevention by Desensitizing Agents.
Acta
Physiol. Acad. Sci. Hung.
1961, 19, 113-131.
43. Szikszay, M.; Obal, F., Jr.; Obal, F. Dose-response
Relationship
in the Thermoregulatory Effects of Capsaicin.
Naunyn-Schmiedeberg's Arch. Pharmacol. 1982, 320,
97-100.
44. Szallasi, A.; Szolcsanyi, J.; Szallasi, Z.; Blumberg, P. M.
Inhibition of [3H]Resiniferatoxin Binding to Rat Dorsal
Root Ganglion
Membranes as a Novel Approach in Evaluating Compounds with
Capsaicin-like Activity. Naunyn-Schmiedeberg's Arch.
Pharmacol. 1991, 344, 551-556.
45. Szallasi, A.; Blumberg, P. M. Vanilloid Receptor Loss in
Rat
Sensory Ganglia Associated with Long Term Densitization to
Resiniferatoxin. Neurosci. Lett.
1992, 136,
51-54.
compd |
affinity (Ki, |
Hill coefficient |
capsaicin (1) |
2.0 ± 0.3 |
2.0 ± 0.2 |
RTX (2) |
0.000 02 |
2.3 ± 0.1 |
capsazepine (3) |
1.2 ± 0.1 |
2.4 ± 0.2 |
6a |
0.6 ± 0.3 |
1.1 ± 0.2 |
6b |
0.4 ± 0.2 |
1.7 ± 0.3 |
6c |
0.2 ± 0.1 |
1.4 ± 0.3 |
6d |
0.2 ± 0.2 |
1.5 ± 0.2 |
6e |
0.4 ± 0.1 |
1.1 ± 0.1 |
6f |
2.2 ± 0.1 |
1.0 ± 0.1 |
10 |
0.3 ± 0.1 |
1.3 ± 0.1 |
12a |
>10 |
|
12b |
1.3 ± 0.1 |
0.9 ± 0.1 |
13 |
>10 |
|
14 |
1.7 ± 0.7 |
1.0 ± 0.1 |
a Mean ± SEM; each experiment was performed at least three times.